Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tovorafenib
- Development stage
- Approved
- Lead developer
- Day One Biopharmaceuticals
- Modality
- Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Fragment-Derived Small Molecules → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Tovorafenib is an oral, brain-penetrant, highly-selective type II RAF kinase inhibitor designed to target a key enzyme in the MAPK signaling pathway. It inhibits mutant BRAF serine-threonine kinase (including V600E and V600D mutations), wild-type BRAF, and wild-type CRAF kinases. Tovorafenib blocks dysregulated signaling pathways related to cancer cell growth and survival without inducing paradoxical activation of the MAPK pathway. It is primarily indicated for pediatric patients (6 months and older) with relapsed or refractory low-grade glioma harboring a BRAF fusion/rearrangement or BRAF V600 mutation[1][2][3][4][5][7][9]. The drug was granted accelerated approval by the FDA in April 2024 as the first systemic therapy for this indication[7]. Tovorafenib has also received Breakthrough Therapy and Orphan Drug designations from regulatory agencies[4].
- Brand names
- Ojemda
- Other names
- tovorafenib
02
Targets
ARAF (Proto-oncogene serine/threonine-protein kinase A-Raf)RAF1 (c-Raf-1 (Y340D/Y341D))BRAF V600E
Beyond the preview
Go deeper on tovorafenib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tovorafenib.